Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — For the past 19 months, the White House Office of Science and Technology Policy has operated with a skeleton crew. For over a year, the top-ranking adviser has not even been a scientist, but rather a 30-something political science major who most recently worked for Silicon Valley billionaire Peter Thiel. Desperate former employees even set up a secret shadow network to provide advice to lawmakers.

Gone are the days when science was high on the agenda, when a staff of more than a hundred helped coordinate the federal government’s response to the Ebola outbreak, launched the Precision Medicine Initiative to personalize health treatments, and spearheaded a $100 million BRAIN Initiative that boosted research into conditions like Alzheimer’s and Parkinson’s disease. Gone, too, is the president who might fire off a marshmallow cannon at 1600 Pennsylvania Ave.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The Investors must be getting restless. It is highly doubtful this poor fellow will bring much science to D.C. No physicians spoke out about the lack of science, facts or data in Healthcare. Too many are financially invested in the current regime.

Comments are closed.